Edition:
United States

Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

1.80USD
4:00pm EDT
Change (% chg)

$-0.17 (-8.63%)
Prev Close
$1.97
Open
$1.98
Day's High
$1.98
Day's Low
$1.78
Volume
139,875
Avg. Vol
78,552
52-wk High
$4.09
52-wk Low
$1.45

Chart for

About

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response... (more)

Overall

Beta: --
Market Cap(Mil.): $147.14
Shares Outstanding(Mil.): 74.31
Dividend: --
Yield (%): --

Financials

  SRRA.OQ Industry Sector
P/E (TTM): -- 95.67 30.17
EPS (TTM): -0.61 -- --
ROI: -31.66 3.33 12.67
ROE: -31.66 2.31 14.86

BRIEF-Sierra Oncology Reports Qtrly Loss Per Share $0.19

* SIERRA ONCOLOGY INC - SRA737 MONOTHERAPY PHASE 1/2 TRIAL EXPANDED TO ENROLL CCNE1-DRIVEN OVARIAN CANCER COHORT

May 10 2018

BRIEF-Sierra Oncology Announces Pricing Of Public Offering Of Common Stock

* SIERRA ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Mar 02 2018

BRIEF-Sierra Oncology Announces Proposed Public Offering Of Common Stock

* SIERRA ONCOLOGY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 01 2018

BRIEF-Sierra Oncology Significantly Expands Clinical Development Program

* SIERRA ONCOLOGY SIGNIFICANTLY EXPANDS CLINICAL DEVELOPMENT PROGRAM

Feb 27 2018

BRIEF-Sierra Oncology Reports Qtrly Loss Of $0.20 Per Share

* SIERRA ONCOLOGY INC - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.20‍​

Feb 27 2018

Earnings vs. Estimates